Skip to main content
Explore URMC

menu

Head and Neck Cancer: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Research Question:
What is the safety, tolerability and anti-tumor activity of the research study drug pembrolizumab (MK-3475) in combination with chemoradiation (CRT) to placebo in combination with CRT in subjects with locally advanced head and neck squamous cell carcinoma?

Basic Study Information

Purpose:
You will be assigned to one of two possible study drug treatments: pembrolizumab or placebo in addition to chemoradiation. you have a 1 in 2 chance of getting placebo, neither you or your study doctor will know which of these you are receiving.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03040999?term=3475-412&rank=1
Study Reference #: IHAN17023

Lead Researcher (Principal Investigator)

Lead Researcher: Ronald Maggiore

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Squamous Cell

Return to Search